Patents by Inventor Cristina Garcia-Paredes
Cristina Garcia-Paredes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230373922Abstract: The present invention provides phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds, to pharmaceutical compositions comprising the compounds, to methods of using the compounds to treat physiological disorders such as cancer.Type: ApplicationFiled: April 13, 2023Publication date: November 23, 2023Inventors: Marta Maria Cifuentes-Garcia, Maria Cristina Garcia Paredes
-
Publication number: 20230373919Abstract: This invention provides certain piperidine compounds as AT2R antagonists, e.g., compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, and X are as defined herein, pharmaceutical compositions thereof, and methods of using the same to treat pain associated with AT2R activity.Type: ApplicationFiled: May 11, 2023Publication date: November 23, 2023Inventors: Thomas James BEAUCHAMP, Zhaogen CHEN, Scott Eugene CONNER, Jon Andre ERICKSON, Maria Cristina GARCIA PAREDES, Jayana Pankajkumar LINESWALA, Emanuele SHER, Bishnu THAPA, Leonard Larry WINNEROSKI, II
-
Patent number: 11655214Abstract: The present invention provides phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds, such as compounds of formula I: pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat physiological disorders such as pancreatic cancer.Type: GrantFiled: April 11, 2018Date of Patent: May 23, 2023Assignee: ELI LILLY AND COMPANYInventors: Marta Maria Cifuentes-Garcia, Maria Cristina Garcia Paredes
-
Patent number: 11028074Abstract: The present invention provides 5-[5]-[2-cycloalkyl]-6-pyridazin-3-yl]-1H-pyrimidine-2,4-dione compounds, or pharmaceutically acceptable salts thereof, that inhibit the activity of CD73 and are useful in treating cancer.Type: GrantFiled: February 22, 2019Date of Patent: June 8, 2021Assignee: Eli Lilly and CompanyInventors: Robert Dean Dally, Maria Cristina Garcia Paredes, Lawrence Joseph Heinz, II, Jennifer Marie Howell, Frank George Njoroge, Yan Wang, Genshi Zhao
-
Publication number: 20210002257Abstract: The present invention provides 5-[5]-[2-cycloalkyl]-6-pyridazin-3-yl]-1H-pyrimidine-2,4-dione compounds, or pharmaceutically acceptable salts thereof, that inhibit the activity of CD73 and are useful in treating cancer.Type: ApplicationFiled: February 22, 2019Publication date: January 7, 2021Inventors: Robert Dean DALLY, Maria Cristina GARCIA PAREDES, Lawrence Joseph HEINZ II, Jennifer Marie HOWELL, Frank George NJOROGE, Yan WANG, Genshi ZHAO
-
Publication number: 20140294763Abstract: The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel steroselective processes to intermediates. The invention is also directed to pharmaceutical compositions and to methods for using the compounds for inhibiting HCV protease or treating a patient suffering from an HCV infection or physiological condition related to the infection. Also provided are pharmaceutical combinations comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compounds having anti HCV activity and a pharmaceutically acceptable carrier, and methods for treating or preventing a HCV infection in a patient using the compositions. The present invention is also directed to a kit or pharmaceutical pack for treating or preventing HCV infection in a patient.Type: ApplicationFiled: June 17, 2014Publication date: October 2, 2014Inventors: Robert Edward Babine, Shu Hui Chen, Ivan Collado-Cano, Maria Cristina Garcia Paredes, John Irvin Glass, Ling Jin, Jason Eric Lamar, Raymond Samuel Parker, III, Nancy June Snyder, Xicheng David Sun, Deqi Guo, Yvonne Yee Mai Yip, May Q. Wang, Victor Frantz, Mark Joseph Tebbe, Robert B. Perni, Luc J. Farmer
-
Patent number: 8529882Abstract: The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel stereoselective processes to intermediates. The invention is also directed to pharmaceutical compositions and to methods for using the compounds for inhibiting HCV protease or treating a patient suffering from an HCV infection or physiological condition related to the infection. Also provided are pharmaceutical combinations comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compounds having anti HCV activity and a pharmaceutically acceptable carrier, and methods for treating or preventing a HCV infection in a patient using the compositions. The present invention is also directed to a kit or pharmaceutical pack for treating or preventing HCV infection in a patient.Type: GrantFiled: July 3, 2012Date of Patent: September 10, 2013Assignee: Vertex Pharmaceuticals IncorporatedInventors: Robert Edward Babine, Shu Hui Chen, Ivan Collado, Cristina Garcia-Paredes, John Irvin Glass, Ling Jin, Jason Eric Lamar, Raymond Samuel Parker, III, Nancy June Snyder, Xicheng David Sun, Deqi Guo, Yvonne Yee Mai Yip, Q. May Wang, Frantz Victor, Mark Joseph Tebbe, Robert B. Perni, Luc Farmer
-
Publication number: 20120282219Abstract: The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel stereoselective processes to intermediates. The invention is also directed to pharmaceutical compositions and to methods for using the compounds for inhibiting HCV protease or treating a patient suffering from an HCV infection or physiological condition related to the infection. Also provided are pharmaceutical combinations comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compounds having anti HCV activity and a pharmaceutically acceptable carrier, and methods for treating or preventing a HCV infection in a patient using the compositions. The present invention is also directed to a kit or pharmaceutical pack for treating or preventing HCV infection in a patient.Type: ApplicationFiled: July 3, 2012Publication date: November 8, 2012Applicant: VERTEX PHARMACEUTICALS INCORPORATEDInventors: ROBERT EDWARD BABINE, SHU HUI CHEN, IVAN COLLADO, CRISTINA GARCIA-PAREDES, JOHN IRVIN GLASS, DEQI GUO, LING JIN, JASON ERIC LAMAR, RAYMOND SAMUEL PARKER, III, NANCY JUNE SNYDER, XICHENG DAVID SUN, MARK JOSEPH TEBBE, FRANTZ VICTOR, Q. MAY WANG, YVONNE YEE MAI YIP, ROBERT B. PERNI, LUC FARMER
-
Patent number: 8252923Abstract: The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel steroselective processes to intermediates. The invention is also directed to pharmaceutical compositions and to methods for using the compounds for inhibiting HCV protease or treating a patient suffering from an HCV infection or physiological condition related to the infection. Also provided are pharmaceutical combinations comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compounds having anti HCV activity and a pharmaceutically acceptable carrier, and methods for treating or preventing a HCV infection in a patient using the compositions. The present invention is also directed to a kit or pharmaceutical pack for treating or preventing HCV infection in a patient.Type: GrantFiled: September 8, 2008Date of Patent: August 28, 2012Assignee: Vertex Pharmaceuticals IncorporatedInventors: Robert Edward Babine, Shu-Hui Chen, Jason Eric Lamar, Nancy June Snyder, Xicheng Sun, Mark Joseph Tebbe, Frantz Victor, Q. May Wang, Yvonne Yee Mai Yip, Ivan Collado, Cristina Garcia-Paredes, Raymond Samuel Parker, III, Ling Jin, Deqi Guo, John Irvin Glass
-
Publication number: 20120064034Abstract: The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel steroselective processes to intermediates. The invention is also directed to pharmaceutical compositions and to methods for using the compounds for inhibiting HCV protease or treating a patient suffering from an HCV infection or physiological condition related to the infection. Also provided are pharmaceutical combinations comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compounds having anti HCV activity and a pharmaceutically acceptable carrier, and methods for treating or preventing a HCV infection in a patient using the compositions. The present invention is also directed to a kit or pharmaceutical pack for treating or preventing HCV infection in a patient.Type: ApplicationFiled: November 10, 2011Publication date: March 15, 2012Applicant: VERTEX PHARMACEUTICALS INCORPORATEDInventors: ROBERT EDWARD BABINE, SHU HUI CHEN, IVAN COLLADO, CRISTINA GARCIA-PAREDES, JOHN IRVIN GLASS, DEQI GUO, LING JIN, JASON ERIC LAMAR, RAYMOND SAMUEL PARKER, III, NANCY JUNE SNYDER, XICHENG DAVID SUN, YVONNE YEE MAI YIP, Q. MAY WANG, FRANTZ VICTOR, MARK JOSEPH TEBBE, ROBERT B. PERNI, LUC FARMER
-
Patent number: 7855211Abstract: The present invention provides a compound of formula (I): or a pharmaceutically acceptable salt thereof which is useful in the treatment of cell proliferative diseases.Type: GrantFiled: December 15, 2009Date of Patent: December 21, 2010Assignee: Eli Lilly and CompanyInventors: David A Coates, Lawrence Mark Gelbert, John M. Knobeloch, Alfonso De Dios Magana, Ana De Prado Gonzalez, Miriam Filadelfa Del Prado Catalina, Maria Cristina Garcia Paredes, Eva Maria Martin De La Nava, Maria Dolores Martin Ortega Finger, Jose Antonio Martinez Perez, Ana Isabel Mateo Herranz, Carlos Perez Martinez, Concepcion Sanchez Martinez
-
Patent number: 7820671Abstract: The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel steroselective processes to intermediates. The invention is also directed to pharmaceutical compositions and to methods for using the compounds for inhibiting HCV protease or treating a patient suffering from an HCV infection or physiological condition related to the infection. Also provided are pharmaceutical combinations comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compounds having anti HCV activity and a pharmaceutically acceptable carrier, and methods for treating or preventing a HCV infection in a patient using the compositions. The present invention is also directed to a kit or pharmaceutical pack for treating or preventing HCV infection in a patient.Type: GrantFiled: August 31, 2001Date of Patent: October 26, 2010Assignee: Vertex Pharmaceuticals IncorporatedInventors: Robert Edward Babine, Shu Hui Chen, Ivan Collado, Cristina Garcia-Paredes, John Irvin Glass, Deqi Guo, Ling Jin, Jason Eric Lamar, Raymond Samuel Parker, III, Nancy June Snyder, Xicheng David Sun, Mark Joseph Tebbe, Frantz Victor, Q. May Wang, Yvonne Yee Mai Yip, Robert B. Perni, Luc Farmer
-
Publication number: 20100160340Abstract: The present invention provides a compound of formula (I): or a pharmaceutically acceptable salt thereof which is useful in the treatment of cell proliferative diseases.Type: ApplicationFiled: December 15, 2009Publication date: June 24, 2010Inventors: David A. COATES, Lawrence Mark GELBERT, John M. KNOBELOCH, Alfonso DE DIOS MAGANA, Ana DE PRADO GONZALEZ, Miriam FILADELFA DEL PRADO CATALINA, Maria Cristina GARCIA PAREDES, Eva Maria MARTIN DE LA NAVA, Maria Dolores MARTIN ORTEGA FINGER, Jose Antonio MARTINEZ PEREZ, Ana Isabel MATEO HERRANZ, Carlos PEREZ MARTINEZ, Concepcion SANCHEZ MARTINEZ
-
Publication number: 20100137583Abstract: The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel steroselective processes to intermediates. The invention is also directed to pharmaceutical compositions and to methods for using the compounds for inhibiting HCV protease or treating a patient suffering from an HCV infection or physiological condition related to the infection. Also provided are pharmaceutical combinations comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compounds having anti HCV activity and a pharmaceutically acceptable carrier, and methods for treating or preventing a HCV infection in a patient using the compositions. The present invention is also directed to a kit or pharmaceutical pack for treating or preventing HCV infection in a patient.Type: ApplicationFiled: September 8, 2008Publication date: June 3, 2010Inventors: Robert Edward Babine, Shu-Hui Chen, Jason Eric Lamar, Nancy June Snyder, Xicheng Sun, Mark Joseph Tebbe, Frantz Victor, Q. May Wang, Yvonne Yee Mai Yip, Ivan Collado, Cristina Garcia-Paredes, Raymond Samuel Parker, III, Ling Jin, Deqi Guo, John Irvin Glass
-
Patent number: 7582638Abstract: The present invention provides kinase inhibitors of Formula (I) wherein R1, R2, and X are as described herein, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: October 23, 2006Date of Patent: September 1, 2009Assignee: Eli Lilly and CompanyInventors: Alfonso De Dios, Cristina Garcia-Paredes, Beatriz López de Uralde Garmendia, Mary Margaret Mader, Mark Andrew Pobanz, Chuan Shih, Boyu Zhong
-
Publication number: 20090062358Abstract: The present invention is directed to compounds represented by the following structural formula, and pharmaceutically acceptable salts, solvates and hydrates thereof, R1 is a substituted or unsubstituted group selected from C1-C8 alkyl, aryl-C0-2-alkyl, heteroaryl-C0-2-alkyl, C3-C6 cycloalkylaryl-C0-2-alkyl or phenyl. W is O or S. R2 is H or a substituted or unsubstituted group selected from C1-C6 alkyl, C3-C6 cycloalkyl and heteroaryl. X is a C2-C5 alkylene linker wherein one carbon atom of the linker may be replaced with O, NH or S. Y is C, O, S, NH or a single bond. Furthermore, E is (CH2)nCOOH, wherein n is 0, 1, 2 or 3, or C(R3)(R4)A, wherein A is an acidic functional group such as carboxyl, carboxamide substituted or unsubstituted sulfonamide, or substituted or unsubstituted tetrazole. R3 is H, saturated or unsaturated C1-C5 alkyl, C1-C5 alkoxy.Type: ApplicationFiled: July 26, 2007Publication date: March 5, 2009Inventors: Ivan Collado Cano, Samuel James Dominianni, Garret Jay Etgen, JR., Cristina Garcia-Paredes, Richard Duane Johnston, Michael Edward Letourneau, Nathan Bryan Mantlo, Michael John Martinelli, Daniel Ray Mayhugh, Ashraf Saeed, Richard Craig Thompson, Xiaodong Wang, David Scott Coffey, Christopher Randall Schmid, Jeffrey Thomas Vicenzi, Yanping Xu
-
Publication number: 20080275056Abstract: The present invention provides kinase inhibitors of Formula (I) wherein R1, R2, and X are as described herein, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: October 23, 2006Publication date: November 6, 2008Inventors: Alfonso De Dios, Cristina Garcia-Paredes, Beatriz Lopez Uralde Garmendia, Mary Margaret Mader, Mark Andrew Pobanz, Chuan Shih, Boyu Zhong
-
Patent number: 7169777Abstract: The present invention relates to melanocortin receptor agonist of the formula I useful in the treatment of obesity, diabetes, and male and/or female sexual dysfunctionType: GrantFiled: January 23, 2002Date of Patent: January 30, 2007Assignee: Eli Lilly and CompanyInventors: Ryan Thomas Backer, Karin Briner, Ivan Collado Caño, Oscar De Frutos Garcia, Christopher William Doecke, Matthew Joseph Fisher, Cristina Garcia-Paredes, Steven Lee Kuklish, Vincent Mancuso, Michael John Martinelli, Ana Isabel Mateo Herranz, Jeffrey Thomas Mullaney, Paul Leslie Ornstein, Zhipei Wu, Chaoyu Xie
-
Publication number: 20050197299Abstract: The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel steroselective processes to intermediates. The invention is also directed to pharmaceutical compositions and to methods for using the compounds for inhibiting HCV protease or treating a patient suffering from an HCV infection or physiological condition related to the infection. Also provided are pharmaceutical combinations comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compounds having anti HCV activity and a pharmaceutically acceptable carrier, and methods for treating or preventing a HCV infection in a patient using the compositions. The present invention is also directed to a kit or pharmaceutical pack for treating or preventing HCV infection in a patient.Type: ApplicationFiled: August 31, 2001Publication date: September 8, 2005Inventors: Robert Babine, Shu-Hul Chen, Jason Lamar, Nancy Snyder, Xicheng Sun, Mark Tebbe, Frantz Victor, Q. Wang, Yvonne Yip, Ivan Collado, Cristina Garcia-Paredes, Raymond Parker, Ling Jing, Deqi Guo, John Glass
-
Publication number: 20040116699Abstract: The present invention relates to melanocortin receptor agonist of the formula I useful in the treatment of obesity, diabetes, and male and/or female sexual dysfunction 1Type: ApplicationFiled: July 11, 2003Publication date: June 17, 2004Inventors: Ryan Thomas Backer, Karin Briner, Ivan Collado Cano, Oscar De Frutos Garcia, Christopher William Doecke, Matthew Joseph Fisher, Cristina Garcia-Paredes, Steven Lee Kuklish, Vincent Mancuso, Michael John Martinelli, Ana Isabel Mateo Herranz, Jeffrey Thomas Mullaney, Paul Leslie Ornstein, Zhipei Wu, Chaoyu Xie